Dr Reddy's Laboratories - 15 Year Stock Price History | RDY
Historical daily share price chart and data for Dr Reddy's Laboratories since 2011 adjusted for splits and dividends. The latest closing stock price for Dr Reddy's Laboratories as of September 18, 2026 is 12.19.
- The all-time high Dr Reddy's Laboratories stock closing price was 16.57 on August 21, 2024.
- The Dr Reddy's Laboratories 52-week high stock price is 15.67, which is 28.5% above the current share price.
- The Dr Reddy's Laboratories 52-week low stock price is 11.36, which is 6.8% below the current share price.
- The average Dr Reddy's Laboratories stock price for the last 52 weeks is 13.50.
| Dr Reddy's Laboratories Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 13.1854 | 13.7218 | 15.2266 | 11.3000 | 12.1900 | -12.30% |
| 2025 | 13.9382 | 15.4173 | 15.9092 | 12.1606 | 13.9000 | -10.53% |
| 2024 | 14.3518 | 13.1827 | 16.5703 | 12.5369 | 15.5353 | 19.96% |
| 2023 | 11.4094 | 9.4857 | 13.5438 | 9.4637 | 12.9500 | 36.47% |
| 2022 | 9.7860 | 11.4744 | 11.4744 | 8.4884 | 9.4894 | -17.50% |
| 2021 | 11.4215 | 12.1651 | 12.9649 | 9.9036 | 11.5025 | -5.54% |
| 2020 | 9.2614 | 6.6926 | 12.3684 | 5.7467 | 12.1771 | 81.46% |
| 2019 | 6.3414 | 6.1676 | 7.0196 | 5.7583 | 6.7108 | 8.43% |
| 2018 | 5.5191 | 6.1991 | 6.4351 | 4.6367 | 6.1889 | 1.24% |
| 2017 | 6.3112 | 7.3434 | 7.5470 | 4.9004 | 6.1129 | -16.46% |
| 2016 | 7.4479 | 7.3388 | 8.7704 | 6.6267 | 7.3175 | -1.67% |
| 2015 | 9.0322 | 8.0160 | 10.8981 | 7.0012 | 7.4417 | -7.79% |
| 2014 | 7.3894 | 6.4076 | 9.3405 | 6.1484 | 8.0703 | 23.71% |
| 2013 | 5.8189 | 5.4034 | 6.5491 | 5.0620 | 6.5236 | 23.99% |
| 2012 | 4.9941 | 4.7264 | 5.4961 | 4.2969 | 5.2612 | 14.04% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $10.175B | $3.580B |
| Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $45.423B | 17.88 |
| BridgeBio Pharma (BBIO) | United States | $13.021B | 0.00 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.445B | 20.49 |
| Bausch Health Cos (BHC) | Canada | $2.121B | 1.32 |
| Personalis (PSNL) | United States | $1.717B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.636B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.005B | 9.45 |
| Assembly Biosciences (ASMB) | United States | $0.508B | 24.48 |
| Sol-Gel Technologies (SLGL) | Israel | $0.169B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.042B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |